Dr. Martin Heidecker, Chief Investment Officer of the AMR Action Fund, contributed to a white paper titled, “The Reckoning of Antimicrobial Resistance: A New Biological Frontier,” published by Cavenagh Health. “Promising equity investment opportunities exist in this space, however, properly assessing them requires investors to take into account several key considerations,” he writes. Heidecker provides insights around clinical trial design, management, and attractive exits.
Read the full paper here.
